Cargando…
The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis
BACKGROUND: Cardiovascular disease is a leading cause of death in ANCA-associated vasculitis (AAV). An expansion of CD4(+)CD28(null) T cells is seen mainly in cytomegalovirus (CMV)-seropositive individuals and has been linked to increased cardiovascular disease risk in other conditions. The aims of...
Autores principales: | Chanouzas, Dimitrios, Sagmeister, Michael, Dyall, Lovesh, Sharp, Phoebe, Powley, Lucy, Johal, Serena, Bowen, Jessica, Nightingale, Peter, Ferro, Charles J., Morgan, Matthew D., Moss, Paul, Harper, Lorraine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116544/ https://www.ncbi.nlm.nih.gov/pubmed/30157919 http://dx.doi.org/10.1186/s13075-018-1695-8 |
Ejemplares similares
-
Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
por: Chanouzas, Dimitrios, et al.
Publicado: (2016) -
Subclinical Reactivation of Cytomegalovirus Drives CD4(+)CD28(null) T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Chanouzas, Dimitrios, et al.
Publicado: (2019) -
Cytomegalovirus infection is a risk factor for venous thromboembolism in ANCA-associated vasculitis
por: King, C., et al.
Publicado: (2022) -
Rituximab 500 mg 6-monthly infusions is an option in maintenance
therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021) -
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
por: King, Catherine, et al.
Publicado: (2017)